BODY COMPOSITION
Does Ipamorelin Cause Weight Gain? The Evidence
The animal record is split: weight and fat went up in some studies, while the marketing leans on fat loss. Here is what was actually measured.
The short answer first
Does ipamorelin cause weight gain? In animals, sometimes yes — and that surprises people who expect a fat-loss peptide. In mice, two weeks of ipamorelin raised body weight by about 15% and increased fat-pad weight, even in animals that could not make their own growth hormone [6]. It also acts on the "hunger hormone" receptor, which can raise appetite [7]. At the same time, in a chemotherapy model it protected against weight loss [5]. So the truthful answer is: the direction depends on the situation, and there is no human study showing it makes a healthy adult leaner. The popular fat-loss reputation rests on growth-hormone mechanism and gym anecdote, not on controlled human outcome trials.
Why weight can go up: the GH-independent effect
The clearest weight-gain evidence comes from a 2001 mouse study. Twice-daily subcutaneous ipamorelin for two weeks raised body weight by roughly 15% in both GH-deficient (lit/lit) and GH-intact mice, with fat-pad weight and serum leptin elevated in both groups [6]. The GH-deficient result is the important one: because those mice could not mount a normal growth-hormone response, the weight and fat gain had to come through a different channel — direct ghrelin-receptor (GHS-R1a) signaling. This is why ipamorelin's body-composition effect cannot be reduced to "it raises GH, so it burns fat." Part of it is an orexigenic, fat-favoring effect baked into the ghrelin mechanism itself.
The appetite angle
Weight change and appetite are linked here. Ipamorelin is a ghrelin mimetic, and ghrelin is the body's hunger signal. Central administration of ghrelin and GH secretagogues activates the hypothalamic appetite centers and induces feeding in rats [7] — a class-level mechanism, not unique to ipamorelin. In community reports, some users describe a noticeable uptick in hunger in the hours after injecting, milder than with the older peptide GHRP-6 but still real (anecdotal, not clinical evidence). For anyone trying to lose weight, an appetite bump is a meaningful confounder — it can quietly raise calorie intake regardless of any effect on growth hormone.
The other direction: protection against weight loss
Ipamorelin's weight effect is not one-directional. In the most recent in-vivo study, a 2024 ferret model of chemotherapy-induced wasting, intraperitoneal ipamorelin (1–3 mg/kg) reduced cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase [5]. That is a protective, anti-cachexia effect — preserving weight in a catabolic state, through a peripheral mechanism, with no anti-nausea benefit. It points to a possible role in wasting conditions rather than in cosmetic fat loss, and it is the kind of finding the broader research field is actually pursuing.
What this means for the 'fat-loss peptide' reputation
The lean-body-composition reputation that drives interest in ipamorelin is mostly an extrapolation from growth-hormone biology — GH favors lipolysis and lean mass — plus the failed-but-suggestive idea that a clean GH pulse should reshape body composition. The actual ipamorelin data complicates that: a GH pulse that does not always raise IGF-1 [4], fat and leptin that went up in mice [6], appetite stimulation built into the mechanism [7], and no human body-composition trial of any kind. The honest summary: ipamorelin demonstrably moves weight and adiposity in animals, but the assumption that it reliably produces fat loss in healthy humans is unproven. The reported, anecdotal leanness people describe is on the Ipamorelin effects page.